AstraZeneca (LON:AZN) has been assigned a GBX 6,500 ($84.14) price objective by research analysts at Barclays in a report issued on Friday, July 27th. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Barclays’ price objective points to a potential upside of 6.44% from the stock’s previous close.
A number of other analysts have also weighed in on AZN. Berenberg Bank set a GBX 6,000 ($77.67) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, April 24th. Deutsche Bank reaffirmed a “buy” rating on shares of AstraZeneca in a report on Monday, April 9th. Jefferies Financial Group set a GBX 5,650 ($73.14) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, April 13th. JPMorgan Chase & Co. set a GBX 5,500 ($71.20) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Friday, April 13th. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 22nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of GBX 5,577.36 ($72.20).
Shares of AstraZeneca traded up GBX 31 ($0.40), hitting GBX 6,107 ($79.06), during midday trading on Friday, according to MarketBeat.com. The company’s stock had a trading volume of 1,938,710 shares, compared to its average volume of 2,310,000. AstraZeneca has a one year low of GBX 4,260 ($55.15) and a one year high of GBX 5,520 ($71.46).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What does RSI mean?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.